• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Global Biologics CDMO Market Report 2022: A Market Valued at $9.9 Billion in 2020 – Competitive Developments, Strategies, Mergers and Acquisitions & New Product Developments to 2026

Share:

February 21, 2022

The “Global Biologics CDMO Market (2022 Edition) – Analysis By Type (Mammalian, Non-Mammalian), Product Type (Biologics, Biosimilars), By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)” report has been added to ResearchAndMarkets.com’s offering.

Global Biologics CDMO Market was valued at USD 9.9 Billion in the year 2020.

Growth opportunities for the Biologics CDMO market are attributed to the growth of the geriatric population, rising technical advancements by the CDMO service providers, increasing trend of outsourcing the drug development processes in the world, and increasing number of research and development activities by some of the key market players in the global platform.

In addition, increasing per capita disposable income, rising global healthcare expenditure along the demand for new therapeutic drugs in the market are driving the Biologics CDMO market.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Moreover, with the rising prevalence of diseases in the world, it is expected that there will be more demand for new drugs which is likely to push the growth of Biologics CDMOs. Also, the rising number of pharmaceutical companies in the emerging economies, increasing demand for novel therapeutic applications along high demand for biologics are the major factors propelling the market growth.

Furthermore, the increased outsourcing trend by small and large pharmaceutical companies provides a promising opportunity for contract development and manufacturing organizations (CDMOs).

The outbreak of COVID-19 will influence the biologics CDMO market in the forecast period as well. This is due to the demand for vaccines and therapeutic antibodies which are expected to continue for several years.

In addition to the economic and social burden, the pandemic has prompted government bodies to increase funding for vaccine development on a global scale. With the ongoing crisis, there has been an immense burden on the healthcare sector worldwide and has impacted the discovery, research, and development of many medicines pushing the growth of the Biologics CDMO industry further.

Read more here

Source: Finance.Yahoo

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Using the 3M’s to Get Physicians to Embrace Telehealth: Metrics, Money & eMotionUsing the 3M’s to Get Physicians to Embrace Telehealth: Metrics, Money & eMotion
  • Halozyme Completes Antares Pharma AcquisitionHalozyme Completes Antares Pharma Acquisition
  • Early Smart Clothing Firm Omsignal is Out of BusinessEarly Smart Clothing Firm Omsignal is Out of Business
  • Merck Officially Commences $1.36B Imago BuyoutMerck Officially Commences $1.36B Imago Buyout
  • RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue MultiplexingRareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing
  • Report: How the COVID-19 Pandemic is Changing Patient CommunicationsReport: How the COVID-19 Pandemic is Changing Patient Communications
  • Adaptas Solutions Completes Acquisition of Applied Kilovolts and Analytical Instrumentation Business from L3Harris TechnologiesAdaptas Solutions Completes Acquisition of Applied Kilovolts and Analytical Instrumentation Business from L3Harris Technologies
  • Acquisition Rumors Continue to Circulate Around Aurinia as GSK Denies InterestAcquisition Rumors Continue to Circulate Around Aurinia as GSK Denies Interest

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications